Centiva Capital, LP Affimed N.V. Transaction History

Centiva Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $67,862 - $103,909	-18,391 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $98,759 - $130,024	18,391 New	18,391 $102,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $69,565 - $94,303	-12,557 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $97,693 - $143,149	12,557 New	12,557 $107,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $502M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.